The post Travel tips for people with MS: A comprehensive guide appeared first on MS Australia. Source: www.msaustralia.org.au
Category: Multiple Sclerosis Research
Helping healthcare providers support people with MS through exercise
The post Helping healthcare providers support people with MS through exercise appeared first on MS Australia. Source: www.msaustralia.org.au
MS Nurses share knowledge and help shape future care at Auckland meeting
The post MS Nurses share knowledge and help shape future care at Auckland meeting appeared first on MS Australia. Source: www.msaustralia.org.au
Promising early results for a new BTK inhibitor for progressive MS
The post Promising early results for a new BTK inhibitor for progressive MS appeared first on MS Australia. Source: www.msaustralia.org.au
At the holidays, MS turns sensory input into neurological overload
The holidays have a way of turning up the volume on everything. The lights feel brighter, rooms feel busier, and even soft conversation seems amplified. Living with multiple sclerosis (MS) has taught me that this kind of noise isn’t just sound — it’s work. It’s one of the reasons my Thanksgiving table has grown smaller…
Two-protein blood test may better track MS activity, disability
Simultaneously measuring levels of two blood proteins — glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) — may offer a clearer way to track both disease activity and disability progression in people with multiple sclerosis (MS), according to a new long-term study. Each marker is tied to a different clinical outcome: NfL helps…
MS patients face higher risk of death by suicide: Analysis
People with multiple sclerosis (MS) have a higher risk of dying by suicide than the general population, according to a meta-analysis of published studies. Nearly one-quarter of participants in the studies had thoughts about suicide (suicidal ideation). Across the studies, 0.5% of participants died by suicide, which represented 2.1% of all deaths observed in people…
Fenebrutinib in PPMS
Tweet Roche announced in early Oct that their BTKi (Bruton’s Tyrosine Kinase inhibitor) was non-inferior to ocrelizumab (anti-B-cell) in PPMS. In a pivotal PPMS study (FENtrepid), fenebrutinib slowed disability progression at least as effectively as OCREVUS, the only approved therapy in PPMS [Ad hoc announcement pursuant to Art. 53 LR] This was measured by a…
Fall at the Mall
A shopping trip goes awry I’m pleased to report that I’ve still got it! Even as I approach my middle ages, I still can pull it off. Just a few weeks ago, I was picked up by not one, but two younger guys! Here’s how it went down. I had a doctor’s appointment in the…
New MS experimental therapy misses main goals in clinical trial
A Phase 2 clinical trial testing PIPE-307, an experimental therapy designed to support myelin repair in people with multiple sclerosis (MS), has failed to meet its primary or secondary efficacy goals. The U.S.-based VISTA trial (NCT06083753) enrolled more than 180 adults with relapsing-remitting MS (RRMS). Participants received one of two PIPE-307 doses or a placebo…